Penumbra Continues Push Into Peripheral Therapies
Penumbra Inc. continues its push into peripheral therapies with the recent US introduction of the POD Packing Coil, designed to occlude arteries and veins in conjunction with the company's Ruby and POD (Penumbra Occlusion Device) embolization products for the treatment of peripheral vascular conditions such as aneurysms and fistulas. The POD Packing coil, which earned a 510(k) in 2015 along with a neurovascular version of the device, grew out of the platinum coil technologies used to treat brain aneurysm.
You may also be interested in...
Randomized trial results show pharmacomechanical, catheter-directed thrombolysis does not reduce the development of post-thrombotic syndrome in patients treated for deep-vein thrombosis. The study’s investigator suggests limiting the procedure to treatment of large iliofemoral blood clots causing major symptoms in patients who are at low risk of bleeding.
Manufacturers of UK personal care products watch out, the Competition and Markets Authority is on the look-out for false, exaggerated and/or vague sustainability claims, and may be targeting bigger players to make an example for the rest of the sector. And consumer health might be next. HBW Insight returns to advice from marketing expert Jo Stephenson on how to avoid greenwashing, based on the CMA's own extensive Green Claims Code.
One outcome of last year’s public consultation on UK MHRA fees is a hefty uplift in charges payable by medtech manufacturers in 2023, beyond which the agency is keen to pursue a new fees and charges plan.